[{"StockholdersEquityConverted_0_Q3_USD":215813000.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_3_Q3_USD":-303453000.0,"CommonStockSharesOutstanding_0_Q3_shares":122542410.0,"StockholdersEquity_0_Q3_USD":163756000.0,"EarningsPerShareBasic_1_Q3_USD":-0.98,"EarningsPerShareBasic_3_Q3_USD":-2.79,"RevenuesConverted_1_Q3_USD":8127000.0,"RevenuesConverted_3_Q3_USD":8127000.0,"Assets_0_Q3_USD":787693000.0,"CommonStockSharesConverted_0_Q3_shares":124957091.0,"NetIncomeLossConverted_1_Q3_USD":-115859000.0,"NetIncomeLossConverted_3_Q3_USD":-328743000.0,"Ticker":"BBIO","CIK":"1743881","name":"BRIDGEBIO PHARMA, INC.","OfficialName":"BridgeBio Pharma Inc. Common Stock","form":"10-Q","period":"20200930","fy":"2020.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1594164456.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20201105"}]